Theriva Biologics sets 1-for-30 reverse split; stock crashes after-hours

Theriva Biologics (TOVX) announced a 1-for-30 reverse stock split, effective December 1, 2026, to meet NYSE listing requirements. Shares will trade on a split-adjusted basis from December 2. The stock crashed in after-hours trading.

Original reporting
Published Nov 20, 2026, 9:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 20, 2026, 9:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Theriva Biologics sets 1-for-30 reverse split; stock crashes after-hours — source image
Decision brief

The 30-second read

$TOVXBearishMed
01

Why it matters

The disclosed 1-for-30 ratio and effective dates create a near-term catalyst for price action, spreads, and order-book behavior, with sentiment often turning negative for microcaps.

02

Market read

A company-specific reverse split is a direct trading catalyst, especially for microcaps where liquidity and compliance narratives can dominate.

03

What to watch

The article truncates the stated NYSE rationale, so traders should verify the exact compliance trigger and whether additional financing or delisting risk is implied.

Relevance 7/10Novelty 8/10Timing: after-hours announcement, with split-adjusted trading starting Dec. 2

Background

Reverse splits reduce share count and can be used to regain or maintain exchange listing compliance.

Company-level read

Ticker impact

$TOVXBearishHigh confidence
Context

Theriva Biologics announced a 1-for-30 reverse split effective Dec. 1, with trading on a split-adjusted basis starting Dec. 2.

Expected impact

Likely downside pressure and higher volatility as the market prices in dilution or continued balance-sheet concerns tied to the reverse split.

Evidence & confidence

The article discloses the company-specific corporate action timing (effective date and first split-adjusted trading day), which typically drives immediate sentiment and technical trading effects for microcaps.

Market effects

Limited spillover, but reinforces that small-cap biotech reverse splits remain a recurring stress signal.

Minimal, primarily affects US microcap trading liquidity and technical levels.

Low, no cross-market linkage indicated.

Counterpoint

The reverse split could be a technical compliance step (e.g., listing requirements) rather than an immediate fundamental deterioration, so selling may be overdone.

Key entities

  • Theriva Biologics

    Announced a 1-for-30 reverse stock split effective Dec. 1, 2026, with split-adjusted trading beginning Dec. 2.

  • NYSE

    The company statement references a need to meet NYSE requirements, though the specific requirement is not fully shown in the excerpt.

Related articles

$TOVXMed

Theriva Biologics, Inc. (TOVX): Theriva™ Biologics Reports Third Quarter 2026 Operational Highlights and Financial Results

Theriva Biologics, Inc. (TOVX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Theriva™ Biologics Reports Third Quarter 2026 Operational Highlights and Financial Results – VIRAGE2 enrollment expected to complete in Q4 2026; initial data expected by Q3 2027 – – Company completes sale of SYN-004 (ribaxamase) and related portfolio of antibiotic-de

$TOVXMed

Theriva Biologics, Inc. (TOVX): Completion of Acquisition or Disposition of Assets

Theriva Biologics, Inc. (TOVX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Theriva™ Biologics Announces Sale of SYN-004 (ribaxamase) and Related Antibiotic-Degrading Enzyme Portfolio to Biossil Labs Inc. - Theriva received a $350,000 upfront payment at closing and is eligible for up to $91 million in regulatory and sales milestones, along w

$TOVXHighAI 9/10

Theriva™ Biologics Announces Publication of the Results from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine

Theriva™ Biologics (NYSE American: TOVX) announced the publication of VIRAGE Phase 2b trial results for VCN-01 in metastatic pancreatic cancer in Nature Medicine. The study showed improved survival and response rates when VCN-01 was combined with standard chemotherapy. Theriva is now evaluating more frequent dosing in the VIRAGE2 Phase 2a trial and exploring VCN-01 for pediatric retinoblastoma.

$TOVXMed

Theriva Biologics, Inc. (TOVX): Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results

Theriva Biologics, Inc. (TOVX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results – First patients dosed in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) the goal of which is to improve tr